Multiparametric MRI’s positive predictive value for detecting prostate cancer improves when lower apparent diffusion coefficient (ADC) values and patient prostate-specific antigen density (PSAD) thresholds data are incorporated, investigators have found.
Multiparametric MRI :1. T2-weighted imaging (T2WI): High-resolution anatomical detail, especially useful for identifying tumor boundaries, 2. Diffusion-weighted imaging (DWI): Detects restricted water movement in tissues, which often correlates with high cellular density seen in cancer, 3. Dynamic contrast-enhanced imaging (DCE): Shows vascularity and contrast uptake patterns that can signal aggressive tumors, 4. MR spectroscopy: Assesses tissue chemistry, though less common in routine practice.
Advantages over standard MRI or biopsy alone: 1. Higher detection rates for clinically significant prostate cancer,2. Improved lesion localization for targeted biopsy, 3. Better tumor staging by showing extracapsular extension or seminal vesicle invasion.
Clinical applications: 1.Used before the first biopsy in high-risk patients or after a negative biopsy when suspicion remains, 2. Reporting follows PI-RADS (Prostate Imaging Reporting and Data System) to standardize interpretation, 3. Prostate multiparametric MRI (mpMRI) with MRI/ultrasound fusion biopsy improves the detection of clinically significant prostate cancer (csPCa) compared with systematic biopsy alone.